JP2022514352A5 - - Google Patents
Info
- Publication number
- JP2022514352A5 JP2022514352A5 JP2021535552A JP2021535552A JP2022514352A5 JP 2022514352 A5 JP2022514352 A5 JP 2022514352A5 JP 2021535552 A JP2021535552 A JP 2021535552A JP 2021535552 A JP2021535552 A JP 2021535552A JP 2022514352 A5 JP2022514352 A5 JP 2022514352A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- alkyl
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784291P | 2018-12-21 | 2018-12-21 | |
| US62/784,291 | 2018-12-21 | ||
| US201962863853P | 2019-06-19 | 2019-06-19 | |
| US62/863,853 | 2019-06-19 | ||
| PCT/US2019/068189 WO2020132661A2 (en) | 2018-12-21 | 2019-12-21 | Inhibitors of fibroblast activation protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022514352A JP2022514352A (ja) | 2022-02-10 |
| JP2022514352A5 true JP2022514352A5 (https=) | 2022-12-28 |
Family
ID=71101996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535552A Pending JP2022514352A (ja) | 2018-12-21 | 2019-12-21 | 線維芽細胞活性化タンパク質の阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11504364B2 (https=) |
| EP (1) | EP3898654A4 (https=) |
| JP (1) | JP2022514352A (https=) |
| CN (1) | CN113811529A (https=) |
| WO (1) | WO2020132661A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11780821B2 (en) | 2017-12-15 | 2023-10-10 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| JP2022516555A (ja) * | 2019-01-04 | 2022-02-28 | プラクシス バイオテック エルエルシー | 線維芽細胞活性化タンパク質の阻害剤 |
| EP4096677A4 (en) * | 2020-01-31 | 2024-02-28 | Purdue Research Foundation | Fibroblast activation protein (fap) - targeted antifibrotic therapy |
| CN115943312A (zh) | 2020-05-07 | 2023-04-07 | 法国居里学院 | 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途 |
| CN114380795A (zh) * | 2020-10-22 | 2022-04-22 | 四川大学华西医院 | 氘代fap抑制剂及其应用 |
| CN114621155A (zh) * | 2020-12-14 | 2022-06-14 | 四川科伦药物研究院有限公司 | 一种制备卡马替尼的方法 |
| EP4263535A1 (en) * | 2020-12-17 | 2023-10-25 | Astrazeneca AB | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| EP4122499A1 (en) * | 2021-07-23 | 2023-01-25 | 3B Pharmaceuticals GmbH | Fibroblast activation protein inhibitors and use thereof |
| WO2023233023A1 (en) | 2022-06-03 | 2023-12-07 | Universiteit Antwerpen | Inhibitors of fibroblast activation protein |
| IL317722A (en) * | 2022-06-21 | 2025-02-01 | Astrazeneca Ab | Solid state forms of N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide |
| JP2025525344A (ja) * | 2022-06-21 | 2025-08-05 | アストラゼネカ・アクチエボラーグ | Ｎ－（２－（４－シアノチアゾリジン－３－イル）－２－オキソエチル）－キノリン－４－カルボキサミド |
| EP4543869A1 (en) * | 2022-06-21 | 2025-04-30 | Astrazeneca AB | N-(2-(3-cyano-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| WO2025037000A1 (en) | 2023-08-17 | 2025-02-20 | Universiteit Antwerpen | Novel fibroblast activation protein inhibitors and medical uses thereof |
| WO2025046043A1 (en) | 2023-08-31 | 2025-03-06 | Stichting Radboud Universitair Medisch Centrum | Endometriosis tracer |
| WO2025106939A1 (en) * | 2023-11-16 | 2025-05-22 | Praxis Biotech LLC | Conjugates targeting fibroblast activation protein and uses thereof |
| WO2025106926A1 (en) * | 2023-11-16 | 2025-05-22 | Praxis Biotech LLC | Conjugates targeting fibroblast activation protein and uses thereof |
| CN120400145A (zh) * | 2025-04-03 | 2025-08-01 | 江南大学 | 基因fap在制备非酒精性脂肪型肝炎的药物中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4357293B2 (ja) | 2001-06-27 | 2009-11-04 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
| WO2004071454A2 (en) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv |
| US7399869B2 (en) | 2005-05-19 | 2008-07-15 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| CA2617715A1 (en) | 2005-08-11 | 2007-02-15 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising a dpp-iv inhibitor |
| EP1760076A1 (en) | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| CN101230058A (zh) | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
| US8338450B2 (en) | 2007-09-21 | 2012-12-25 | Lupin Limited | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors |
| WO2009116067A2 (en) | 2008-01-10 | 2009-09-24 | Sun Pharma Advanced Research Company Limited | Novel derivatives of acyl cyanopyrrolidines |
| WO2010083570A1 (en) | 2009-01-23 | 2010-07-29 | The University Of Sydney | Novel metabolic disease therapy |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| EP2730571A1 (en) | 2012-11-12 | 2014-05-14 | Universitat De Barcelona | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
| CA2991628C (en) | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| WO2017189569A1 (en) | 2016-04-25 | 2017-11-02 | Trustees Of Tufts College | Multimediator dpp4 and fap inhibitors, and uses related thereto |
| CN116474108A (zh) * | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| JP7071366B2 (ja) | 2016-12-14 | 2022-05-18 | メディミューン，エルエルシー | 注射情報を取得して送信するための、プランジャロッド内に埋設された多部品センサ |
| EA202090776A1 (ru) | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| US11780821B2 (en) | 2017-12-15 | 2023-10-10 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| EP3749663A1 (en) | 2018-02-06 | 2020-12-16 | Universität Heidelberg | Fap inhibitor |
| JP2022516555A (ja) | 2019-01-04 | 2022-02-28 | プラクシス バイオテック エルエルシー | 線維芽細胞活性化タンパク質の阻害剤 |
-
2019
- 2019-12-21 US US16/724,198 patent/US11504364B2/en active Active
- 2019-12-21 CN CN201980092135.6A patent/CN113811529A/zh active Pending
- 2019-12-21 WO PCT/US2019/068189 patent/WO2020132661A2/en not_active Ceased
- 2019-12-21 EP EP19901288.1A patent/EP3898654A4/en not_active Withdrawn
- 2019-12-21 JP JP2021535552A patent/JP2022514352A/ja active Pending
-
2022
- 2022-09-14 US US17/944,963 patent/US20230144841A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514352A5 (https=) | ||
| JP2022516555A5 (https=) | ||
| IL275333B2 (en) | Inhibitors of fibroblast activation protein | |
| JP5046922B2 (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| JP2022017295A5 (https=) | ||
| RU2008115454A (ru) | Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272 | |
| JP2007501238A (ja) | 癌の治療および阻害のための上皮増殖因子受容体キナーゼ阻害剤と細胞障害性物質との組み合わせの使用 | |
| JP2008531576A5 (https=) | ||
| RU2011118227A (ru) | Способ лечения рака | |
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| EP3042669B1 (en) | Antitumor agent and antitumor effect enhancer | |
| JP2011506402A5 (https=) | ||
| RU2016127634A (ru) | Гетероциклические модуляторы синтеза липидов для применения против рака и вирусных инфекций | |
| Lindenblatt et al. | Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model | |
| RU2020109775A (ru) | Комплексная терапия | |
| CA2797182A1 (en) | Methods of enhancing antibody-dependent cellular cytotoxicity | |
| TWI752147B (zh) | [6r]-亞甲基四氫葉酸-在基於5-氟尿嘧啶的化療中有效的葉酸替代物 | |
| RU2014112320A (ru) | Ингибитор pi3k, предназначенный для применения для лечения рака кости или для предупреждения метастатической диссеминации первичных раковых клеток в кость | |
| JP2022535609A5 (https=) | ||
| RU2004136989A (ru) | Цианогуанидиновые пролекарства | |
| TW202102216A (zh) | 抗腫瘤組合物 | |
| JP2021533090A5 (https=) | ||
| WO2020111234A1 (ja) | 組み合わせ医薬として用いられるｅｚｈ１／２二重阻害剤を含有する医薬組成物 | |
| RU2004136991A (ru) | Цианогуанидиновые пролекарства | |
| JP2008527039A5 (https=) |